Your institution may have access to this item. Find your institution then sign in to continue.
Title
MARKETPLACE: Drug & therapeutics update.
Abstract
The article offers updates on several therapeutic drugs. It states that the kinase inhibitor Votrient™ from GlaxoSmithKline has become a treatment for advanced soft tissue carcinoma's selective subtypes among adult patients. It says that Genentech Inc.'s Perjeta™ is a recombinant humanized monoclonal antibody. It adds that kinase inhibitor Affinitor® from Novartis Pharmaceuticals Corp. can already treat renal angiomyolipoma in adults.